Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.